Walgreen Co.

Tim Wentworth, CEO since October 2023, sets the strategic direction for corporate development and capital allocation. Before joining Walgreens, he led Express Scripts and served as founding CEO of Evernorth, Cigna's health services division, giving him deep experience in pharmacy benefit management and healthcare M&A. Major acquisition decisions — like the VillageMD and Shields Health Solutions deals — are approved by the board of directors and executed by the corporate development team.

Walgreens sources acquisition targets through its position as one of the largest retail healthcare payers and pharmacy networks in the US. The company's dispensing data, prescription volume, and physical footprint give it visibility into specialty pharmacy providers, primary care consolidators, and digital health platforms that can be integrated into its store network. The Shields Health Solutions acquisition originated from an existing commercial partnership that demonstrated the value of specialty pharmacy within Walgreens' ecosystem.

Neither — Walgreens is a publicly traded corporation that uses its corporate balance sheet for strategic acquisitions, not a family office or venture firm. Unlike a traditional investment fund, it does not raise third-party LP capital or charge management fees. The company holds acquired entities like VillageMD and Shields as consolidated subsidiaries, operating them as part of an integrated healthcare platform rather than maintaining a portfolio of independent investments.

Walgreens' healthcare investments are overwhelmingly direct corporate acquisitions and majority-stake buyouts. The company does not operate an LP fund-of-funds program for external venture or private equity managers. The closest exception is the transition of its early-stage healthcare venture arm — which previously made minority investments — into a strategy that now prioritizes full integration of acquired assets.

The company targets mature, revenue-generating healthcare services businesses that can scale within its retail pharmacy network. VillageMD was a growth-stage primary care platform with hundreds of clinics before the majority acquisition; Shields Health Solutions was a profitable specialty pharmacy integrator serving hospital systems. Walgreens does not typically engage in seed or early-stage venture investing with its corporate treasury.

Walgreens has been willing to structure deals with minority co-investors. When it paid $5.2B for a majority stake in VillageMD, the transaction was structured as a mixed debt-and-equity investment that left existing VillageMD management and outside investors — including private equity backers — with a continuing minority interest. The intent in such structures is to maintain operating alignment while giving Walgreens control over integration.

The Walgreens corporate foundation makes charitable grants focused on health equity and community pharmacy access, but it is a standard corporate foundation separate from the company's investment and M&A activities. It does not function as a family-office style DAF or a private philanthropic trust tied to any individual family's wealth.